Globestar Therapeutics Corp. (GSTC)
OTC PINK OTC PINK Primary Summary
Globestar Therapeutics Corp. (GSTC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Globestar Therapeutics Corp. ever had a stock split?
Globestar Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | James C. Katzaroff CEO | OTC PINK Exchange | 37960P104 CUSIP |
| US Country | - Employees | - Last Dividend | 30 Jun 2015 Last Split | - IPO Date |
Overview
GlobeStar Therapeutics Corporation is a clinical stage pharmaceutical entity, formerly known as AngioSoma, Inc., which underwent a name change in July 2021. Based in Richland, Washington, the company is primarily focused on the development of a patented formulation of drugs aimed at treating multiple sclerosis and other neurodegenerative diseases. This focus places GlobeStar Therapeutics Corporation at the forefront of addressing some of the most challenging conditions in the neurodegenerative disease spectrum, leveraging advanced scientific research and innovation to bring new therapies to the market.
Products and Services
- Amethyst:
An innovative compound developed by GlobeStar Therapeutics Corporation, Amethyst is designed to target and treat neurodegenerative diseases, with a specific focus on multiple sclerosis. It represents the company's commitment to advancing treatment options for patients suffering from these challenging conditions. By focusing on neurodegeneration, Amethyst has the potential to significantly impact the quality of life for individuals affected by these diseases, offering hope and new possibilities for disease management and therapy.
